FP09.05 Driver Oncogenic Alterations and Indoor Radon in NSCLC Patients From the IFCT Biomarker Cohort: Bioradon France Study

Archive ouverte

Mezquita, L. | Barlesi, F. | Ielsch, G. | Merlio, J. | Debieuvre, D. | Mosser, J. | Ricordel, C. | Ouafik, L'Houcine | Rouquette, I. | Monnet, I. | Escande, F. | Langlais, A. | Morin, F. | Vignaud, C. | Auclin, E. | Benitez, J.C. | Planchard, D. | Leuraud, K. | Laurier, D. | Besse, B. | Westeel, V.

Edité par CCSD ; Lippincott, Williams & Wilkins -

International audience. Those with FH of LC were more likely to be obese regardless of demographic factors, and less likely to exercise 2+ times per week (Table). Those with FH of LC were more likely to have received 10+ imaging scans and to have been exposed to hydrocarbons compared to those without FH (Table). There were no reported differences in any other occupational or home exposures, including asbestos and radon in those with v. without FH of LC (Table). Conclusion: FH of LC is associated with higher-risk behaviors that increase the likelihood of developing both lung and other cancers. As such, FH can be used in cancer prevention and control programs to identify higher-risk patients and educate patients that FH of lung cancer is associated with risk-increasing behaviors that are nonetheless modifiable.

Suggestions

Du même auteur

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program

Archive ouverte | Leduc, C. | CCSD

BACKGROUND: EGFR mutations cause inconsistent response to EGFR tyrosine-kinase inhibitors (TKI). To better understand these features, we reviewed all cases of EGFR-mutated non-small-cell lung cancer collected in the Biomarkers Fra...

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer

Archive ouverte | Molinier, O. | CCSD

International audience. Background: Immunotherapy using inhibitors targeting immune checkpoint programmed cell death protein 1 (PD-1)/ programmed death-ligand 1 (PD-L1) is currently the standard of care in patients ...

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

Archive ouverte | Beau-Faller, M. | CCSD

International audience. BACKGROUND: There is scarce data available about epidermal growth factor receptor (EGFR) mutations other than common exon 19 deletions and exon 21 (L858R) mutations. PATIENTS AND METHODS: EGF...

Chargement des enrichissements...